Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
Jie Tian, Yong-Ping Song, Gao-Chong Zhang, Shu-Fang Wang, Xiao-Xiang Chu, Ye Chai, Chun-Ling Wang, Ai-Li He, Feng Zhang, Xu-Liang Shen, Wei-Hua Zhang, Lin-Hua Yang, Da-Nian Nie, Dong-Mei Wang, Huan-Ling Zhu, Da Gao, Shi-Feng Lou, Ze-Ping Zhou, Guo-Hong Su, Yan Li, Jin-Ying Lin, Qing-Zhi Shi, Gui-Fang Ouyang, Hong-Mei Jing, Sai-Juan Chen, Jian Li, Jian-Qing Mi
J Cancer Res Clin Oncol 150(4) 189
摘要
摘要
PURPOSE: The synergistic effects of combining arsenic compounds with imatinib against chronic myeloid leukemia (CML) have been established using in vitro data. We conducted a clinical trial to compare the efficacy of the arsenic realgar-indigo naturalis formula (RIF) plus imatinib with that of imatinib monotherapy in patients with newly diagnosed chronic phase CML (CP-CML). METHODS: In this multicenter, randomized, double-blind, phase 3 trial, 191 outpatients with newly diagnosed CP-CML were randomly assigned to receive oral RIF plus imatinib (n = 96) or placebo plus imatinib (n = 95). The primary end point was the major molecular response (MMR) at 6 months. Secondary end points include molecular response 4 (MR4), molecular response 4.5 (MR4.5), progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: The median follow-up duration was 51 months. Due to the COVID-19 pandemic, the recruitment to this study had to be terminated early, on May 28, 2020. The rates of MMR had no significant statistical difference between combination and imatinib arms at 6 months and any other time during the trial. MR4 rates were similar in both arms. However, the 12-month cumulative rates of MR4.5 in the combination and imatinib arms were 20.8% and 10.5%, respectively (p = 0.043). In core treatment since the 2-year analysis, the frequency of MR4.5 was 55.6% in the combination arm and 38.6% in the imatinib arm (p = 0.063). PFS and OS were similar at five years. The safety profiles were similar and serious adverse events were uncommon in both groups. CONCLUSION: The results of imatinib plus RIF as a first-line treatment of CP-CML compared with imatinib might be more effective for achieving a deeper molecular response (Chinadrugtrials number, CTR20170221).
KM 提取结果
0 个 Figure · 0 个 KM 面板